Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer

Clinical Therapeutics

Volumn 27, Issue 6, 2005, Pages 684-694

  Wong, Siu Fun ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Cetuximab; Chemotherapy; Colorectal cancer; Epidermal growth factor receptor monoclonal antibody

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN;

ABDOMINAL PAIN; ACNE; ALLERGIC REACTION; ANEMIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG TOLERABILITY; DYSPNEA; FEVER; HUMAN; HYPERSENSITIVITY REACTION; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; METASTASIS; MONOTHERAPY; MORTALITY; NAUSEA; PARONYCHIA; RASH; REVIEW; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 27744607673     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.06.003     Document Type: Review

References (47)

1. Cancer Facts and Figures 2004. American Cancer Society, Inc; 2004. Available at: https://www.cancer.org/ docroot/STT/content/STT-1xCancer_ Facts_Figures_2004.asp. Accessed March 13, 2005.
2. Engstrom PF, Benson A, Saltz L. The NCCN colon cancer clinical practice guidelines in oncology. JNCCN. 2003; 1:40-53.
3. Gunderson L, Sargent DS, Tepper L. Impact of TN stage and treatment on survival and relapse in adjuvant rectal cancer pooled analysis. Proc Am Soc Clin Oncol. 2003;22:251. Abstract 1008.
4. Saltz LB, Cox JV, Blanke C, et al, for the Irinotecan Study Group, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-914.
5. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18: 2938-2947.
7. Hanahan D, Weinberg R. The hallmarks of cancer. Cell. 2000;100:57-70.
8. Carpenter C, Cantley L. Essentials of signal transduction. In: Devita T, Rosenberg S, eds. Cancer Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:31-41.
9. Carpenter G, Cohen S. Epidermal growth factor. Ann Rev Biochem. 1979;48:193-216.
10. Adjei AA, Rowinsky EK. Novel anticancer agents in clinical development. Cancer Biol Ther. 2003;2(Suppl 1): S5-S15.
11. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
12. Syed S, Rowinsky E. The new generation of target therapies for breast cancer. Oncology (Huntingt). 2003;10: 1339-1351.
13. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for anticancer therapy. Cancer Invest. 1999;9:553-562.
14. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
15. Kohler G. The Nobel Lectures in immunology. The Nobel Prize for Physiology or Medicine, 1984. Derivation and diversification of monoclonal antibodies. Scand J Immunol. 1993; 37:117-129.
16. Dillman RO, Shawler DL, McCallister TJ, Halpem SE. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies. Cancer Biotherapy. 1994;9:17-28.
17. Mellstedt H. Monoclonal antibodies in human cancer. Drug Today (Barc). 2003;39(Suppl C):1-16.
18. Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol. 1998;81:105-115.
19. Kawamoto T, Mendelsohn J, Le A, et al. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem. 1984; 259:7761-7766.
20. Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res. 1998;4:2957-2966.
21. Klohs WD, Fry DW, Kraker AJ. Inhibitors of tyrosine kinase. Curr Opin Oncol. 1997;9:562-568.
22. Chan KC, Knox WF, Gee JM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res. 2002; 62:122-128.
23. Woodburn J. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999; 82:241-250.
24. Sato JD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983;1:511-529.
25. Mendelsohn J. Blockade of receptors for growth factors: An anti-cancer therapy-the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000;6:747-753.
26. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993; 85:1327-1333.
27. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53:4637-4642.
28. Robert F, Ezekiel M, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234-3243.
29. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18:904-914.
30. Rubin EH, Doroshow J, Hidalgo M, et al. A study to assess the pharmacokinetics (PK) of a single infusion of cetuximab (IMC-C225). Proceeding (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 3084.
31. Erbitux [cetuximab] for intravenous use only [package insert]. Branchburg, NJ: ImClone Systems Incorporated; and Lawrenceville, NJ: Bristol-Myers Squibb Company; 2004.
32. Folprecht G, Lutz M, Schoeffski P, et al. Pharmacokinetic (PK) evaluation of cetuximab in combination with weekly irinotecan (CPT-11) and 24h infusional 5-FU/folinic acid (FA) as first line treatment in patients (pts) with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2003;22:222. Abstract 890.
33. Fox FE, Mauro D, Bai S, et al. A population pharmacokinetic (PPK) analysis of the anti-EGFr specific IgG1 monoclonal antibody cetuximab. ASCO 2004 Gastrointestinal Cancers Symposium, January 22-24, 2004, San Francisco, Calif. Abstract 290.
34. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
35. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;35:337-345.
36. Tabernero JM, Van Culsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proceeding (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 3512.
37. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proceedings (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 3513.
38. Badarinath S, Mitchell E, Jennis A, et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial. Proceeding (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 3531.
39. Lenz HJ, Mayer R, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proceedings (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 3510.
40. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004; 22:4772-4778.
41. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319. Editorial.
42. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proceeding (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 5507.
43. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Proceeding (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 5502.
44. Lynch TJ, Lilenbaum R, Bonomi P, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proceedings (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 7084.
45. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proceeding (Post-Meeting Edition) of the 2004 ASCO Annual Meeting; June 5-8, 2004; New Orleans, La. J Clin Oncol. 2004;22. Abstract 7012.
46. Kelly K, Hanna N, Rosenberg A, et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol. 2003;22:644. Abstract 2592.
47. Xiong HO, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol. 2004;22:2610-2616.